Table 1 Participant demographics
Whole cohort | Neutralisation assay cohort | |
|---|---|---|
Number of patients | 500 | 94 |
Age (years) | ||
Median | 67 | 71 |
IQR | 60 to 72 | 64 to 77 |
Range | 39 to 89 | 50 to 89 |
Sex | ||
Men | 267 (53%) | 53 (56%) |
Women | 233 (47%) | 41 (44%) |
Vaccine received | ||
Pfizer | 204 (41%) | 48 (51%) |
AstraZeneca | 296 (59%) | 46 (49%) |
Vaccine interval | ||
3-weeks | 16 (3%) | 10 (11%) |
Delayed | 484 (97%) | 84 (89%) |
Delayed vaccine interval (days) | ||
Median | 77 | 77 |
IQR | 70 to 79 | 74 to 80 |
Range | 33 to 133 | 43 to 112 |
Time from second vaccine to blood test (days) | ||
Median | 20 | 28 |
IQR | 17 to 29 | 20 to 37 |
Range | 4 to 133 | 10 to 66 |
Time since CLL diagnosis (months) | ||
Median | 73 | 88 |
IQR | 34 to 133 | 37 to 162 |
Range | 1 to 408 | 5 to 276 |
CLL stage at diagnosis | ||
A | 429 (86%) | 81 (86%) |
B | 30 (6%) | 4 (4%) |
C | 41 (8%) | 9 (10%) |
Previous treatment | ||
Watch and wait | 279 (56%) | 57 (61%) |
Treatment planned | 13 (3%) | 1 (1%) |
1 line | 128 (26%) | 25 (27%) |
2 lines | 48 (10%) | 7 (7%) |
3 + lines | 32 (6%) | 4 (4%) |
On BTKi | 99 (20%) | 20 (21%) |
On venetoclax | 21 (4%) | 1 (1%) |
Previous chemotherapy | 143 (29%) | 24 (26%) |
Previous anti-CD20 | 153 (31%) | 24 (26%) |
History of infection Frequent infections | 145 (29%) | 23 (25%) |
Hospitalisation with infection | 95 (19%) | 14 (15%) |
Prophylactic antibiotics | 37 (7%) | 8 (9%) |
IVIG | 41 (8%) | 2 (2%) |
Immunoglobulin deficiency Number | 471 | 94 |
IgG (< 6 g/L) | 236 (50%) | 40 (43%) |
IgA (< 0.8 g/L) | 232 (49%) | 38 (40%) |
IgM (< 0.5 g/L) | 177 (38%) | 46 (49%) |